Bio-Z-Cough

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for use in patients as determined by the prescribing healthcare professional. Currently, there are no specific indications or usage details provided.

There are no known teratogenic or nonteratogenic effects associated with this drug. Healthcare professionals should consider the absence of these effects when evaluating treatment options for their patients.

Dosage and Administration

The recommended dosage for adults and children aged 12 years and older is 1 teaspoonful (5 mL) administered orally every 4 hours. It is imperative that the total number of doses does not exceed 6 in any 24-hour period. For children under 12 years of age, it is advised to consult a physician for appropriate dosing guidance.

Contraindications

Use of this product is contraindicated in patients currently taking a prescription monoamine oxidase inhibitor (MAOI) for the treatment of depression, psychiatric or emotional conditions, or Parkinson's disease, as well as for a period of 2 weeks following the discontinuation of an MAOI. Patients should consult their doctor or pharmacist if they are uncertain about the presence of an MAOI in their current medications.

Warnings and Precautions

Healthcare professionals should exercise caution when recommending this product. It is imperative to advise patients to consult a physician prior to use if they present with a cough that is associated with excessive phlegm (mucus) or if they have a chronic cough, particularly in cases related to smoking, asthma, chronic bronchitis, or emphysema.

Patients must adhere strictly to the recommended dosage and should not exceed the directed amount. In the event that a cough persists for more than 7 days, recurs, or is accompanied by additional symptoms such as fever, rash, or a persistent headache, it is crucial to discontinue use and seek medical advice. These symptoms may indicate a more serious underlying condition that requires further evaluation.

In cases of suspected overdose, immediate medical assistance should be sought, or the patient should contact a Poison Control Center without delay.

Healthcare providers should remain vigilant and ensure that patients are aware of these warnings and precautions to promote safe and effective use of the product.

Side Effects

Patients should be advised to consult a healthcare professional prior to use if they experience a cough that is associated with excessive phlegm (mucus) or if the cough is chronic, as may occur with conditions such as smoking, asthma, chronic bronchitis, or emphysema.

In addition, patients are instructed to discontinue use and seek medical advice if their cough persists for more than 7 days, recurs, or is accompanied by symptoms such as fever, rash, or a persistent headache. These symptoms may indicate the presence of a serious underlying condition that requires further evaluation.

Drug Interactions

The concomitant use of dextromethorphan hydrobromide with prescription monoamine oxidase inhibitors (MAOIs) is contraindicated. This combination can result in serious interactions. It is advised that dextromethorphan hydrobromide not be administered to patients currently taking an MAOI or within two weeks following the discontinuation of an MAOI.

No additional drug interactions or laboratory test interactions have been identified.

Packaging & NDC

Below are the non-prescription pack sizes of Bio-Z-Cough (dextromethorphan hydrobromide, guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Children under 12 years of age should consult a physician before use. For adults and children aged 12 years and over, the recommended dosage is 1 teaspoonful (5 mL) every 4 hours. It is important to keep this medication out of the reach of children. In the event of an overdose, immediate medical assistance should be sought, or contact a Poison Control Center.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure the safety of both the mother and the developing fetus.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary significantly depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, which may include airway management, intravenous fluids, and monitoring of vital parameters.

If specific antidotes or treatments are available for the substance involved, they should be administered according to established protocols. Consultation with a poison control center or toxicology expert may also be warranted to guide management decisions.

It is crucial to document all findings and interventions in the patient's medical record and to report any adverse events to the appropriate regulatory authorities as required.

Nonclinical Toxicology

No relevant information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no pertinent data concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

No specific adverse reactions or safety updates related to postmarketing experience have been reported.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of the reach of children to prevent accidental ingestion. It is crucial to emphasize the importance of safety in the home environment, particularly for households with young children.

In the event of an overdose, healthcare providers should instruct patients to seek medical help immediately or contact a Poison Control Center. Patients should be made aware of the signs of overdose and the urgency of obtaining assistance to ensure their safety and well-being.

Storage and Handling

The product is supplied in packaging that includes a tamper evident feature. It is essential to inspect the seal under the cap before use; the product should not be used if the seal is torn, broken, or missing.

For optimal storage, the product should be kept at room temperature, specifically within the range of 15 to 30 degrees Celsius (59 to 86 degrees Fahrenheit). It is important to avoid exposure to excessive heat or humidity to maintain the integrity of the product.

Additional Clinical Information

The medication is administered orally. For adults and children aged 12 years and older, the recommended dosage is 1 teaspoonful (5 mL) every 4 hours. For children under 12 years of age, it is advised to consult a physician for appropriate dosing guidance.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Bio-Z-Cough, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)